Clinical Research Of Raltitrexed Plus Oxaliplatin Hyperthermic Intraperitoneal Chemotherapy(HIPEC) After Laparoscopic Radical Resection In Treating Stage T4 Colon Cancer

Objective:To explore the short period curative effect and adverse reactions of Raltitrexed plus Oxaliplatin hyperthermic intraperitoneal chemotherapy for treating stage T4 colon cancer.Methods:Studying on sixty-one cases of advanced colon cancer which were diagnosed by pathology in the Second Affiliated Hospital of Chongqing Medical University from October 2015 to October 2016 were randomly divided into the experimental group,the control group 1 and control group 2.The experimental group consisted of nineteen patients choose Raltitrexed(2mg/m~2)plus Oxaliplatin(100mg/m~2)for HIPEC.The control group 1 consisted of twenty-two patients choose Oxaliplatin(100mg/m~2)for HIPEC.Eight hours after the operation to row first HIPEC treatment,once every two days,for a total of three times.And then underwent the first systemic infusion of mFOLFOX6 regimen within postoperative one month,for a total of 6 cycles(all two HIPEC groups),and another twenty cases only underwent systemic chemotherapy of the same regimen(control group 2).The incidence of adverse effects vital signs and complications,and the 1-and 2-year recurrence and survival rate were compared.Results:All three groups were successfully performed.There were no significant differences in incidence of postoperative complications(P>0.05)except pain.The two groups with HIPEC were more painful and abdominal distention(P<0.05).Three groups of patients in tumor markers significantly lower after treatment than before treatment(P<0.05),Three groups of patients was no statistical significance with in the after treatment and before treatment(P>0.05).There was no difference in 1-year recurrence rate and 1-year survival rate between the three groups(P>0.05).The 2-year recurrence rate in the experimental group was significantly lower than those in control group 1/2(P<0.0167).The control group1 was significantly lower than the control group2(P<0.0167).The 2-year survival rate in the experimental group was significantly higher than the control group 2(P<0.0167),the control group 1 was significantly higher than the control group 2(P<0.0167),but there was no significant differences between the control group 1 and the control group 2(P>0.0167),.Conclusion:Raltitrexed plus Oxaliplatin hyperthermic intraperitoneal chemotherapy(HIPEC)in treating stage T4 colon cancer following radical resection is safe and feasible.It has a better curative effect.